NICE recommends ORGOVYX® (relugolix) as the first oral ADT treatment for hormone sensitive prostate cancer in England

Contributed by: PR Newswire

Tags

Accord-Healthcare-ADT

More Like This

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a new treatment option for patients with advanced prostate cancer

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

MHRA Approves Zolbetuximab

PR Newswire associated0

European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

Organon to Present New Research on Access and Value at ISPOR 2026

PR Newswire associated0

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD